Resumen
Liver transplantation (LT) is the best potentially curative treatment for unresectable, early-stage hepatocellular carcinoma (HCC) in cirrhotic patients. Bridging-to-transplant therapies, including transarterial radioembolization (TARE), are performed to delay tumor progression until the LT can be performed but also offer potential benefits regarding post-transplant progression-free survival. This study confirms the good results of bridging-to-transplant TARE, of LT as a curative treatment of HCC, and also shows the importance of TARE in the palliative, multimodal treatment of patients with HCC.